Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Payables (2016 - 2025)

PAVmed has reported Payables over the past 6 years, most recently at $678000.0 for Q4 2025.

  • For Q4 2025, Payables rose 3.2% year-over-year to $678000.0; the TTM value through Dec 2025 reached $678000.0, up 3.2%, while the annual FY2025 figure was $678000.0, 3.2% up from the prior year.
  • Payables for Q4 2025 was $678000.0 at PAVmed, up from $342000.0 in the prior quarter.
  • Over five years, Payables peaked at $8.2 million in Q1 2022 and troughed at $342000.0 in Q3 2025.
  • A 5-year average of $2.3 million and a median of $1.6 million in 2023 define the central range for Payables.
  • Biggest five-year swings in Payables: surged 275.0% in 2022 and later crashed 84.72% in 2023.
  • Year by year, Payables stood at $3.3 million in 2021, then decreased by 18.04% to $2.7 million in 2022, then crashed by 33.95% to $1.8 million in 2023, then plummeted by 63.21% to $657000.0 in 2024, then increased by 3.2% to $678000.0 in 2025.
  • Business Quant data shows Payables for PAVM at $678000.0 in Q4 2025, $342000.0 in Q3 2025, and $387000.0 in Q2 2025.